Potential of lactoferrin to prevent antibiotic-induced Clostridium difficile infection

Journal of Antimicrobial Chemotherapy

Volumn 71, Issue 4, 2016, Pages 975-985

  Chilton, C H ^a   Crowther, G S ^a   Spiewak K ^b   Brindell, M ^b   Singh, G ^c   Wilcox, M H ^a   Monaghan, T M ^c  

^a UNIVERSITY OF LEEDS   (United Kingdom)

^b JAGIELLONIAN UNIVERSITY   (Poland)

^c NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETIC ACID; ANTIBIOTIC AGENT; BACTERIAL TOXIN; BUTYRIC ACID; CLINDAMYCIN; COPPER; CYTOTOXIN; IRON; ISOBUTYRIC ACID; ISOVALERIC ACID; LACTOFERRIN; MANGANESE; METAL; PROPIONIC ACID; SHORT CHAIN FATTY ACID; VALERIC ACID; ZINC; ANTIINFECTIVE AGENT;

ARTICLE; BACTERIAL COUNT; BACTERIAL SPORE; BACTERIAL STRAIN; BACTERIUM CULTURE; CELL PROLIFERATION; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; HUMAN; INTESTINE FLORA; NONHUMAN; PEPTOCLOSTRIDIUM DIFFICILE; POLYMERASE CHAIN REACTION; RIBOTYPING; SIMULATION; SPORE GERMINATION; BACTERIAL LOAD; CHEMISTRY; CLOSTRIDIUM INFECTIONS; DRUG EFFECTS; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FECES; GASTROINTESTINAL TRACT; INTESTINE; MICROBIOLOGY;

ANTI-BACTERIAL AGENTS; BACTERIAL LOAD; CLINDAMYCIN; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM INFECTIONS; ENTEROCOLITIS, PSEUDOMEMBRANOUS; FECES; GASTROINTESTINAL TRACT; HUMANS; INTESTINES; IRON; LACTOFERRIN; SPORES, BACTERIAL;

EID: 84964319395     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkv452     Document Type: Article

References (61)

1. Rupnik M, Wilcox MH, Gerding DN. Clostridium difficile infection: new developments in epidemiology and pathogenesis. Nat Rev Microbiol 2009; 7: 526-36.
2. Wiegand PN, Nathwani D, Wilcox MH et al. Clinical and economic burden of Clostridium difficile infection in Europe: a systematic review of healthcare-facility-acquired infection. J Hosp Infect 2012; 81: 1-14.
3. Marra F, Ng K. Controversies around epidemiology, diagnosis and treatment of Clostridium difficile Infection. Drugs 2015; 75: 1095-118.
4. Shields K, Araujo-Castillo RV, Theethira TG et al. Recurrent Clostridium difficile infection: from colonization to cure. Anaerobe 2015; 34: 59-73.
5. Soriano MM, Johnson S. Treatment of Clostridium difficile infections. Infect Dis Clin North Am 2015; 29: 93-108.
6. Weinberg ED. Iron availability and infection. Biochimica et Biophysica Acta 2009; 1790: 600-5.
7. Cernat RC, Scott KP. Evaluation of novel assays to assess the influence of different iron sources on the growth of Clostridium difficile. Anaerobe 2012; 18: 298-304.
8. Vorland LH. Lactoferrin: a multifunctional glycoprotein. APMIS 1999; 107: 971-81.
9. Ochoa TJ, Cleary TG. Effect of lactoferrin on enteric pathogens. Biochimie 2009; 91: 30-4.
10. Kane SV, SandbornWJ, Rufo PA et al. Fecal lactoferrin is a sensitive and specific marker in identifying intestinal inflammation. Am J Gastroenterol 2003; 98: 1309-14.
11. Walker TR, Land ML, Kartashov A et al. Fecal lactoferrin is a sensitive and specific marker of disease activity in children and young adults with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 2007; 44: 414-22.
12. Yamamoto T, Shiraki M, Bamba T et al. Fecal calprotectin and lactoferrin as predictors of relapse in patients with quiescent ulcerative colitis during maintenance therapy. Int J Colorectal Dis 2014; 29: 485-91.
13. LaSala PR, Ekhmimi T, Hill AK et al. Quantitative fecal lactoferrin in toxin-positive and toxin-negative Clostridium difficile specimens. J Clin Microbiol 2013; 51: 311-3.
14. Boone JH, DiPersio JR, Tan MJ et al. Elevated lactoferrin is associated with moderate to severe Clostridium difficile disease, stool toxin, and 027 infection. Eur J Clin Microbiol Infect Dis 2013; 32: 1517-23.
15. Archbald-Pannone LR. Quantitative fecal lactoferrin as a biomarker for severe Clostridium difficile infection in hospitalized patients. J Geriatr Palliat Care 2014; 2: 3.
16. Steiner TS, Flores CA, Pizarro TT et al. Fecal lactoferrin, IL-1b, and IL-8 are elevated in patients with severe Clostridium difficile colitis. Clin Diagn Lab Immunol 1997; 4: 719-22.
17. Majka G, Spiewak K, Kurpiewska K et al. A high-throughput method for the quantification of iron saturation in lactoferrin preparations. Anal Bioanal Chem 2013; 405: 5191-200.
18. Chilton CH, Crowther GS, Baines SD et al. In vitro activity of cadazolid against clinically relevant Clostridium difficile isolates and in an in vitro gut model of C. difficile infection. J Antimicrob Chemother 2014; 69: 697-705.
19. Chilton CH, Crowther GS, Todhunter SL et al. Efficacy of alternative fidaxomicin dosing regimens for treatment of simulated Clostridium difficile infection in an in vitro human gut model. J Antimicrob Chemother 2015; 70: 2598-607.
20. Chilton CH, Crowther GS, Todhunter SL et al. Efficacy of surotomycin in an in vitro gut model of Clostridium difficile infection. J Antimicrob Chemother 2014; 69: 2426-33.
21. Chilton CH, Crowther GS, Freeman J et al. Successful treatment of simulated Clostridium difficile infection in a human gut model by fidaxomicin first line and after vancomycin or metronidazole failure. J Antimicrob Chemother 2014; 69: 451-62.
22. Jenssen H, Hancock RE. Antimicrobial properties of lactoferrin. Biochimie 2009; 91: 19-29.
23. Weinberg ED. Antibiotic properties and applications of lactoferrin. Curr Pharm Design 2007; 13: 801-11.
24. Rodriguez-Franco DA, Vazquez-Moreno L, Ramos-Clamont Montfort G. Antimicrobial mechanisms and potential clinical application of lactoferrin. Rev Latinoam Microbiol 2005; 47: 102-11.
25. Baines SD, Freeman J, Wilcox MH. Effects of piperacillin/tazobactam on Clostridium difficile growth and toxin production in a human gut model. J Antimicrob Chemother 2005; 55: 974-82.
26. Freeman J, O'Neill FJ, Wilcox MH. Effects of cefotaxime and desacetylcefotaxime upon Clostridium difficile proliferation and toxin production in a triple-stage chemostat model of the human gut. J Antimicrob Chemother 2003; 52: 96-102.
27. Baines SD, Saxton K, Freeman J et al. Tigecycline does not induce proliferation or cytotoxin production by epidemic Clostridium difficile strains in a human gut model. J Antimicrob Chemother 2006; 58: 1062-5.
28. Saxton K, Baines SD, Freeman J et al. Effects of exposure of Clostridium difficile PCR ribotypes 027 and 001 to fluoroquinolones in a human gut model. Antimicrob Agents Chemother 2009; 53: 412-20.
29. Chilton CH, Freeman J, Crowther GS et al. Co-amoxiclav induces proliferation and cytotoxin production of Clostridium difficile ribotype 027 in a human gut model. J Antimicrob Chemother 2012; 67: 951-4.
30. Crowther GS, Baines SD, Todhunter SL et al. Evaluation of NVB302 versus vancomycin activity in an in vitro human gut model of Clostridium difficile infection. J Antimicrob Chemother 2013; 68: 168-76.
31. Baines SD, O'Connor R, Saxton K et al. Comparison of oritavancin versus vancomycin as treatments for clindamycin-induced Clostridium difficile PCR ribotype 027 infection in a human gut model. J Antimicrob Chemother 2008; 62: 1078-85.
32. Freeman J, Baines SD, Jabes D et al. Comparison of the efficacy of ramoplanin and vancomycin in both in vitro and in vivo models of clindamycin-induced Clostridium difficile infection. J Antimicrob Chemother 2005; 56: 717-25.
33. Freeman J, Baines SD, Saxton K et al. Effect of metronidazole on growth and toxin production by epidemic Clostridium difficile PCR ribotypes 001 and 027 in a human gut model. J Antimicrob Chemother 2007; 60: 83-91.
34. Kanwar JR, Mahidhara G, Kanwar RK. Novel alginate-enclosed chitosan-calcium phosphate-loaded iron-saturated bovine lactoferrin nanocarriers for oral delivery in colon cancer therapy. Nanomedicine 2012; 7: 1521-50.
35. Troost FJ, Steijns J, SarisWHet al. Gastric digestion of bovine lactoferrin in vivo in adults. J Nutr 2001; 131: 2101-4.
36. Vorland LH, Ulvatne H, Rekdal O et al. Initial binding sites of antimicrobial peptides in Staphylococcus aureus and Escherichia coli. Scand J Infect Dis 1999; 31: 467-73.
37. Aguilera O, Ostolaza H, Quiros LM et al. Permeabilizing action of an antimicrobial lactoferricin-derived peptide on bacterial and artificial membranes. FEBS Lett 1999; 462: 273-7.
38. Haukland HH, Ulvatne H, Sandvik K et al. The antimicrobial peptides lactoferricin B and magainin 2 cross over the bacterial cytoplasmic membrane and reside in the cytoplasm. FEBS Lett 2001; 508: 389-93.
39. Ulvatne H, Samuelsen O, Haukland HH et al. Lactoferricin B inhibits bacterial macromolecular synthesis in Escherichia coli and Bacillus subtilis. FEMS Microbiol Lett 2004; 237: 377-84.
40. Wong JM, de Souza R, Kendall CW et al. Colonic health: fermentation and short chain fatty acids. J Clin Gastroenterol 2006; 40: 235-43.
41. Rea MC, O'Sullivan O, Shanahan F et al. Clostridium difficile carriage in elderly subjects and associated changes in the intestinal microbiota. J Clin Microbiol 2012; 50: 867-75.
42. Antharam VC, Li EC, Ishmael A et al. Intestinal dysbiosis and depletion of butyrogenic bacteria in Clostridium difficile infection and nosocomial diarrhea. J Clin Microbiol 2013; 51: 2884-92.
43. Cummings JH, Macfarlane GT. The control and consequences of bacterial fermentation in the human colon. J Appl Bacteriol 1991; 70: 443-59.
44. Roediger WE. Role of anaerobic bacteria in the metabolic welfare of the colonic mucosa in man. Gut 1980; 21: 793-8.
45. Guilloteau P, Martin L, Eeckhaut V et al. From the gut to the peripheral tissues: the multiple effects of butyrate. Nutr Res Rev 2010; 23: 366-84.
46. Furusawa Y, Obata Y, Fukuda S et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature 2013; 504: 446-50.
47. Gibbons JA, Kanwar RK, Kanwar JR. Lactoferrin and cancer in different cancer models. Front Biosci 2011; 3: 1080-8.
48. Samarasinghe RM, Kanwar RK, Kanwar JR. The effect of oral administration of iron saturated-bovine lactoferrin encapsulated chitosannanocarriers on osteoarthritis. Biomaterials 2014; 35: 7522-34.
49. Tsuda H, Kozu T, Iinuma G et al. Cancer prevention by bovine lactoferrin: from animal studies to human trial. Biometals 2010; 23: 399-409.
50. Yao X, Bunt C, Cornish J et al. Oral delivery of bovine lactoferrin using pectin-and chitosan-modified liposomes and solid lipid particles: improvement of stability of lactoferrin. Chem Biol Drug Des 2015; 84: 466-75.
51. Gupta I, Sehgal R, Kanwar RK et al. Nanocapsules loaded with ironsaturated bovine lactoferrin have antimicrobial therapeutic potential and maintain calcium, zinc and iron metabolism. Nanomedicine 2015; 10: 1289-314.
52. Laffan AM, McKenzie R, Forti J et al. Lactoferrin for the prevention of post-antibiotic diarrhoea. J Health Popul Nutr 2011; 29: 547-51.
53. Kanwar JR, Palmano KP, Sun X et al. 'Iron-saturated' lactoferrin is a potent natural adjuvant for augmenting cancer chemotherapy. Immun Cell Biol 2008; 86: 277-88.
54. Furlund CB, Ulleberg EK, Devold TG et al. Identification of lactoferrin peptides generated by digestion with human gastrointestinal enzymes. J Dairy Sci 2013; 96: 75-88.
55. Kalantzi L, Goumas K, Kalioras V et al. Characterization of the human upper gastrointestinal contents under conditions simulating bioavailability/bioequivalence studies. Pharm Res 2006; 23: 165-76.
56. Philip AK, Philip B. Colon targeted drug delivery systems: a review on primary and novel approaches. Oman Med J 2010; 25: 79-87.
57. Macfarlane GT, Macfarlane S, Gibson GR. Validation of a three-stage compound continuous culture system for investigating the effect of retention time on the ecology and metabolism of bacteria in the human colon. Microb Ecol 1998; 35: 180-7.
58. Rivera FP, Medina AM, Bezada S et al. Bovine lactoferrin decreases cholera-toxin-induced intestinal fluid accumulation in mice by ganglioside interaction. PLoS One 2013; 8: e59253.
59. Legrand D, Mazurier J. A critical review of the roles of host lactoferrin in immunity. Biometals 2010; 23: 365-76.
60. Oguchi S, WalkerWA, Sanderson IR. Iron saturation alters the effect of lactoferrin on the proliferation and differentiation of human enterocytes (Caco-2 cells). Biol Neonate 1995; 67: 330-9.
61. Paesano R, Torcia F, Berlutti F et al. Oral administration of lactoferrin increases hemoglobin and total serum iron in pregnant women. Biochem Cell Biol 2006; 84: 377-80.